Global Oncology Biosimilars Market 2016-2020

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Overview of cancer
Epidemiology
Economic burden of cancer

PART 06: Biosimilars industry
Comparison between biosimilars and generic small molecules
Factors influencing biologics and biosimilars
Biosimilars: business and pricing strategy
Factors affecting the uptake of biosimilars
Biosimilar opportunities
Growth of biosimilars 2014– 2020
Market penetration of originators and biosimilars in different regions
Current and future trends in global oncology biosimilars market
Challenges for new entrants

PART 07: Global pharmaceutical market
Market size and forecast
Global biosimilars market

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by end-user
Hospitals
Retail pharmacies

PART 10: Market segmentation by application
Cancer treatment drugs
Supportive care drugs

PART 11: Geographical segmentation
Global oncology biosimilar drugs market by geographical segmentation 2015-2020
Oncology biosimilars market in EMEA
Oncology biosimilars market in APAC
Oncology biosimilars market in Americas

PART 12: Key leading regions
US
Europe
Japan
India
China

PART 13: Market drivers
Rise in number of patent expiries
Increase in prevalence of cancer
Growing aging population
Promising drug pipeline
Need for cost-effective treatment
Favorable government regulations

PART 14: Impact of drivers

PART 15: Market challenges
Risks related to failure of drugs in market
Multiple manufacturing complexities
Reluctance among physicians to prescribe biosimilar products
Complicated regulatory process
Limited availability of biosimilar products
Risk of side effects

PART 16: Impact of drivers and challenges

PART 17: Market trends
Emergence of biosimilars
Outsourcing of biosimilar manufacturing activities
Rising number of strategic collaborations
Increase in cancer awareness
Rise in R&D

PART 18: Vendor landscape
Competitive scenario
Biocon
Celltrion
Dr. Reddy's Laboratories
F Hoffmann-La Roche
Hospira
Mylan
Sandoz
Other prominent vendors

PART 19: Appendix
List of abbreviations

PART 20: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global biosimilars and oncology biosimilars market 2015
Exhibit 03: Cancer burden in European Union (EU)
Exhibit 04: Global incidence of cancer 2015
Exhibit 05: Global mortality of cancer type 2015
Exhibit 06: Estimated numbers of cancer survivors by age in US 2014
Exhibit 07: Definition of biosimilars in different regions
Exhibit 08: Comparison between biosimilars and generic small molecules
Exhibit 09: Factors influencing biologics and biosimilars
Exhibit 10: Impact of biosimilars cost savings on various sectors
Exhibit 11: Factors affecting success of biosimilars
Exhibit 12: Biosimilars industry: Point-of-view
Exhibit 13: Factors affecting the uptake of biosimilars
Exhibit 14: Strategic factors for new entrant
Exhibit 15: Growth of biosimilars
Exhibit 16: Share of biosimilars in recombinant drugs sales in major markets 2014
Exhibit 17: Trends in global oncology biosimilars market
Exhibit 18: Challenges for new entrants
Exhibit 19: Global pharmaceutical market 2015-2020 ($ trillions)
Exhibit 20: Global biosimilars market 2015-2020 ($ billions)
Exhibit 21: Number of approved biosimilars in regulated and semi-regulated markets
Exhibit 22: Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions)
Exhibit 23: Global oncology biosimilars market 2015-2020 ($ billions)
Exhibit 24: Global oncology biosimilars market overview
Exhibit 25: Five forces analysis
Exhibit 26: Oncology biosimilars market segmentation by end-user 2014
Exhibit 27: Global oncology biosimilars segmentation by application
Exhibit 28: Oncology biosimilars by application
Exhibit 29: Global oncology biosimilars market by geographical segmentation 2015
Exhibit 30: Global oncology biosimilars market revenue by geography 2015-2020 ($ billions)
Exhibit 31: Oncology biosimilars market in EMEA 2015-2020 ($ billions)
Exhibit 32: Oncology biosimilars market in APAC 2015-2020 ($ billions)
Exhibit 33: Oncology biosimilars market in Americas 2015-2020 ($ billions)
Exhibit 34: Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 35: Key leading regions
Exhibit 36: Pharmaceutical R&D expenditure in US 2010-2015 ($ billions)
Exhibit 37: Approvals of biologicals versus biosimilars via PHSA
Exhibit 38: Approval process for biosimilars in US
Exhibit 39: Benefits of biosimilars to US healthcare system
Exhibit 40: Role of stake holders
Exhibit 41: SWOT analysis
Exhibit 42: Oncology biosimilars approved by EMA in Europe
Exhibit 43: Guidelines for biosimilars in EU
Exhibit 44: Time line of biosimilars in Europe
Exhibit 45: Key stake holders
Exhibit 46: Key drivers and restraints
Exhibit 47: Biosimilar industry challenges in Europe
Exhibit 48: SWOT analysis
Exhibit 49: Biosimilars approved by PMDA in Japan
Exhibit 50: Review process for biosimilars in Japan
Exhibit 51: Drivers and challenges in oncology biosimilars market in Japan
Exhibit 52: SWOT analysis
Exhibit 53: Biosimilars approved in India
Exhibit 54: Timeline for development of biosimilars in India
Exhibit 55: Challenges and strategies
Exhibit 56: Major domestic and international vendors operating in India
Exhibit 57: Drivers and challenges
Exhibit 58: SWOT analysis
Exhibit 59: Top domestic and international vendors operating in China
Exhibit 60: Drivers and challenges
Exhibit 61: SWOT analysis
Exhibit 62: Patent expiries of oncology biologics in US and EU 2020
Exhibit 63: Global incidence of cancer 2015 and 2020
Exhibit 64: Impact of drivers
Exhibit 65: Impact of drivers and challenges
Exhibit 66: Global competitive landscape 2015
Exhibit 67: Biocon: Key takeaways
Exhibit 68: Celltrion: Key takeaways
Exhibit 69: Dr. Reddy's Laboratories: Key takeaways
Exhibit 70: F. Hoffmann-La: Key takeaways
Exhibit 71: Hospira: Key takeaways
Exhibit 72: Mylan: Key takeaways
Exhibit 73: Sandoz: Key takeaways

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.